Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $48.19 USD
Change Today -0.62 / -1.27%
Volume 629.7K
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

acadia pharmaceuticals inc (ACAD) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/15/15 - $51.99
52 Week Low
08/4/14 - $19.67
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

acadia pharmaceuticals inc (ACAD) Related Businessweek News

No Related Businessweek News Found

acadia pharmaceuticals inc (ACAD) Details

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Its lead product candidate is NUPLAZID, which completed the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis; is in Phase II study for Alzheimer’s disease psychosis; and has completed Phase II trial for the treatment of schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

119 Employees
Last Reported Date: 05/7/15
Founded in 1993

acadia pharmaceuticals inc (ACAD) Top Compensated Officers

Interim Chief Executive Officer, Chief Financ...
Total Annual Compensation: $245.6K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $544.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $489.6K
Executive Vice President, Corporate Complianc...
Total Annual Compensation: $457.0K
Compensation as of Fiscal Year 2014.

acadia pharmaceuticals inc (ACAD) Key Developments

ACADIA Pharmaceuticals Inc. Appoints Ernst & Young LLP as Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2015

ACADIA Pharmaceuticals Inc. has appointed Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2015 at the annual general meeting held on June 15, 2015.

ACADIA Pharmaceuticals Inc. Presents Integrated Efficacy and Tolerability Data from its Phase III Program with NUPLAZID™

ACADIA Pharmaceuticals Inc. announced the presentation of integrated efficacy and tolerability data from its Phase III program with NUPLAZID™ (pimavanserin) at the 19th International Congress of Parkinson’s Disease and Movement Disorders held in San Diego. An integrated analysis was performed on efficacy and tolerability data from two six-week Phase III placebo-controlled clinical trials with NUPLAZID (40 mg) in Parkinson’s disease psychosis (PDP). In this large pooled sample of 268 patients from North America, NUPLAZID showed highly significant improvement in psychosis compared to placebo on the 9-item SAPS-PD scale (p2A receptors that play an important role in psychosis. ACADIA has reported positive Phase III trial results with NUPLAZID, which has the potential to be the first drug approved in the United States for psychosis associated with Parkinson’s disease. NUPLAZID is administered orally once-a-day. ACADIA discovered NUPLAZID and holds worldwide rights to this new chemical entity. The trade name NUPLAZID has been provisionally accepted by the FDA.

ACADIA Pharmaceuticals Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 01:30 PM

ACADIA Pharmaceuticals Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 01:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACAD:US $48.19 USD -0.62

ACAD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Acorda Therapeutics Inc $34.74 USD +0.38
Depomed Inc $31.17 USD -0.33
Impax Laboratories Inc $48.29 USD -0.17
Isis Pharmaceuticals Inc $53.96 USD -0.97
View Industry Companies

Industry Analysis


Industry Average

Valuation ACAD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 52,027.8x
Price/Book 17.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 48,910.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACADIA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at